Predicting and discovering drug-drug interactions (DDIs) is an important problem and has been studied extensively both from medical and machine learning point of view. Almost all of the machine learning approaches have focused on text data or textual representation of the structural data of drugs. We present the first work that uses drug structure images as the input and utilizes a Siamese convolutional network architecture to predict DDIs.
Introduction
Adverse drug events (ADEs) are "injuries resulting from medical intervention related to a drug" (Nebeker, Barach, and Samore 2004) , and are distinct from medication errors (inappropriate prescription, dispensing, usage etc.) as they are caused by drugs at normal dosages. According to the National Center for Health Statistics (NCHS 2014), 48.9% of Americans took at least one prescription drug in the last 30 days, 23.1% took at least three, and 11.9% took at least five. These numbers rise sharply to 90.6%, 66.8% and 40.7% respectively, among older adults (65 years or older). This means that the potential for ADEs is very high in a variety of health care settings including inpatient, outpatient and long-term care settings. For example, in inpatient settings, ADEs can account for as many as one-third of hospital-related complications, affect up to 2 million hospital stays annually, and prolong hospital stays by 2-5 days (DHHS 2010) .
The economic impact of these issues is as widespread as the various healthcare settings and can be staggering. Estimates suggest that ADEs contributed to $3.6 billion in excess healthcare costs in the US alone (Aspden et al. 2007 ). Unsurprisingly, older adults are at the highest risk of being affected by an ADE, and are seven times more likely than younger persons to require hospital admission (Budnitz et al. 2006 ). In the US, as a large number of older adults are Medicare beneficiaries, this economic impact is borne by an already overburdened Medicare system and ultimately passed on to taxpayers and society at large. Beyond older adults, there are several other patient populations that are also vulnerable to ADEs including children, those with lower socio-economic Copyright c 2019, Association for the Advancement of Artificial Intelligence (www.aaai.org). All rights reserved. means, those with limited access to healthcare services, and certain minorities.
Recent research has identified, somewhat surprisingly, that many of these ADEs can be attributed to very common medications (Budnitz et al. 2011 ) and many of them are preventable (Gurwitz and others 2003) or ameliorable (Forster et al. 2005) . This issue motivates our long-term goal of developing accessible and robust means of identifying ADEs in a disease/drug-agnostic manner and across a variety of healthcare settings. Here, we focus on the problem of drug-drug interactions (DDIs), which are a type of ADE. An ADE is characterized as a DDI when multiple medications are co-administered and cause an adverse effect on the patient. DDIs, often caused by inadequate understanding of various drug-drug contraindications, are a major cause of hospital admissions, rehospitalizations, emergency room visits, and even death (Becker et al. 2007 ).
Identifying DDIs is an important task during drug design and testing, and regulatory agencies such as the U. S. Food and Drug Administration require large controlled clinical trials before approval. Beyond their expense and timeconsuming nature, it is impossible to discover all possible interactions during such clinical trials. This necessitates the need for computational methods for DDI prediction. A substantial amount of work in DDI focuses on text-mining (Liu and Chen 2013; Chee, Berlin, and Schatz 2011) to extract DDIs from large text corpora; however, this type of information extraction does not discover new interactions, and only serves to extract in vivo or in vitro discoveries from publications.
Our goal is to discover DDIs in large drug databases by exploiting various properties of the drugs and identifying patters in drug interaction behaviors. Recent approaches consider phenotypic, therapeutic, structural, genomic and reactive properties of drugs (Cheng and Zhao 2014) or their combinations (Dhami et al. 2018) to characterize drug interactivity. We take a fresh and completely new perspective on DDI prediction through the lens of molecular images, a few examples shown in figure 1, via deep learning. Our work is novel in the following significant ways:
• we formulate DDI discovery as a link prediction problem;
• we aim to perform DDI discovery directly on molecu-arXiv:1911.06356v1 [cs.
LG] 14 Nov 2019 lar structure images of the drugs directly, rather than on lossy, string-based representations such as SMILES strings and molecular fingerprints; and
• we utilize deep learning, specifically Siamese networks (Chopra et al. 2005 ) in a contrastive manner to build a DDI discovery engine that can be integrated into a drug database seamlessly.
Related Work
The social and economic impacts of drug-drug interactions have also been well studied and understood. The effect of DDI on medication management and social care is studied in (Arnold et al. 2018) and with its economic impact shown in (Shad, Marsh, and Preskorn 2001) . The impact of DDIs in the elderly patients in 6 Europen countries was documented in (Björkman et al. 2002) and in a similar vein the study by Becker et al. (Becker et al. 2007 ) identifies that the elderly have an increased risk factor ≈ 9 times over the general population with the clinical significance of DDIs studied in (Roberts et al. 1996) . Identification of DDIs can be done by either clinical trials or in vitro and in vivo experiments but these approaches are highly labor-intensive, costly and timeconsuming. Thus, a system that can mitigate these factors is highly desirable. Drug-Drug interactions have been studied extensively both from medical and machine learning point of view. From a medical standpoint (Lau et al. 2003) , (Hirano et al. 2006) and (Wang et al. 2000) showed the effect of important individual drugs and enzymes such as subtrates on various drug-drug interactions. The problem of DDI discovery/prediction is a pairwise classification task and thus kernel-based methods (Shawe-Taylor and Cristianini 2004) are a natural fit since kernels are naturally suited to representing pairwise similarities. Most similarity-based methods for DDI discovery/prediction have used biomedical research literature as the underlying data source and construct NLP-based kernels from these medical documents (Segura-Bedmar, Martinez, and de Pablo-Sánchez 2011;
Chowdhury and Lavelli 2013). Some work has also been done on learning kernels from different types of data such as molecular and structural properties of the drugs and then using these multiple kernels to predict DDIs (Cheng and Zhao 2014; Dhami et al. 2018) .
Siamese 
Siamese Convolutional Network for Drug-Drug Interactions
A discriminative approach for learning a similarity metric using a Siamese architecture was introduced in (Chopra et al. 2005) which maps the input (pair of inputs) into a target space such that the distance between the mappings is minimized in the target space for similar pair of examples and maximized in case of dissimilar examples. We adapt the Siamese architecture for the task of link prediction where the link is whether two drugs interact or not. Since the Siamese architecture results in a measure of similarity between the pair of given inputs it can be thresholded in order to obtain a classification. We use contrastive loss (Hadsell, Chopra, and LeCun 2006), based on a distance metric (Eucledian distance in our case), to learn a parameterized function F to obtain the mapping from the input space to the target space whose function can then be given as
2 is the Eucledian distance between the obtained outputs after the input pairs are processed by the sub-networks. Also m is a margin such that m ≥ 0 that signifies that dissimilar pairs beyond this margin will not contribute to the loss. Figure 2 shows our complete architecture. It consists of two identical sub-networks i.e. networks having same configuration with the same parameters and weights. Each subnetwork takes a gray-scale image of size 500 × 500 × 1 as input (we initially have color images that we convert to gray-scale before feeding to sub-networks as input) and consists of 4 convolutional layers with number of filters as 64, 128, 128 and 256 respectively. The kernel size for each convolutional layer is (9 × 9) and the activation function is relu. The relu is a non-linear activation function is given as f (x) = max(0, x). Each convolutional layer is followed by a max-pooling layer with pool size of (3 × 3) and a batch normalization layer. After the convolutional layers, the subnetwork has 3 fully connected layers with 256, 128 and 20 neurons respectively. Thus after an image pair is processed by the Siamese sub-networks two vectors of dimension 20 × 1 are obtained. Contrastive loss is then applied to the obtained pair of vectors to obtain a distance between the input pair which can then be thresholded to obtain a prediction.
Initially we keep the threshold at 0.5 and then use precision recall curve to identify the best threshold = 0.65. Note that the convolutions in the convolutional sub-network provide translational in-variance property but rotational in-variance is also important in our problem domain. This is because isomers (one of the chiral forms) of drugs are expected to react differently when interacting with a certain drug (Nguyen, He, and Pham-Huy 2006; Chhabra, Aseri, and Padmanabhan 2013). For example, Fenfluramine and Dexfenfluramine are isomers of each other and where Fenfluramine interacts with Acebutolol but Dexfenfluramine does not (Figure 4) . Another example is that the L-isomer of methorphan, Levomethorphan, is an opioid analgesic, while the D-isomer, Dextromethorphan, is a dissociative cough suppressant 1 . We discuss our results next. Figure 3 shows the results for using Siamese network for predicting drug-drug interactions using drug molecular structure images. Our data set consists of images of 373 drugs downloaded from the PubChem database 2 and generate a data set of 19936 drug pairs that interact with each other (Y = 1) and 47424 drug pairs that do not interact with each other (Y = 0). We optimize our Siamese network using the Adam optimization algorithm (Kingma and Ba 2014) with a learning rate of 5 × 10 −5 . The best learning rate was obtained using line search. We also tried the Root Mean Square Propagation (RMSprop) optimizer (Hinton 2012 ) that is an adaptive learning rate method but the results were not encouraging and thus we make use of the Adam optimizer. As mentioned before, we also keep an initial threshold of 0.5 to obtain the predictions after obtaining a distance between pair of drug images using the Siamese convolutional network. We divide the data set into 44457 training and 22903 testing examples. To introduce rotational in-variance we rotate the drug images by 90 • and 180 • and use them to train and test the Siamese network. After including the rotated images the data set size increases to 88914 training and 45806 testing examples. Figure 3(a) shows the accuracy after thresholding the obtained distance at 0.5 and training the network for 20 epochs. The results show that at 0.5 threshold, if the data set includes rotated drug images the network shows better results than if the data set does not include the rotated drug images. We also tried Earth movers or Wassertein distance 3 as the distance metric (Yu and Herman 2005) for the Siamese architecture but it did not make much difference in the final results.
Experiments
We then pick a best threshold using a precision-recall curve such that the best intuitive trade-off between Precision and Recall can be represented and obtain a value of 0.65 as the 3 https://en.wikipedia.org/wiki/Wasserstein metric best threshold. Figures 3(b) and 3(c) present different metrics after training the network for 20 and 50 epochs respectively. The results show that even when the number of epochs are increased the results do not vary much. We present the results with the data set including the images rotated by 180 • since it gives the best accuracy result as seen in figure 3(a). Another important thing to note here is that in our problem formulation recall is the most important factor that should be considered. The simple reason is that we do not want to miss any interaction i.e. a false negative results in much more serious consequences (fatalities in patients) than false positives (monetary losses such as new clinical trials) (Dhami et al. 2018) . Our network achieves a recall of ≈ 85% thereby showing the effectiveness of using a Siamese architecture for predicting DDIs. Along with the high recall we also obtain a high precision of ≈ 75% thereby showing that the Siamese architecture can also extract relevant DDIs.
An important factor also to consider here is the effect of the threshold on the obtained results. With the threshold of 0.5 the effect of rotational in-variance becomes evident as the network when trained with rotated images performs better than when trained without the rotated drug images. After we find the best threshold the effect of rotational in-variance becomes negligible.
Conclusion and Future Work
In this work we focus on using the molecular images of the drugs in a pairwise fashion and feeding them to a rotationinvariant Siamese architecture to predict whether two drugs interact with each other. Our evaluations on the drug images obtained from PubChem database establish the superiority of our proposed approach, which is distinct from current approaches that generally use the drug molecular structure in text format such as the Simplified Molecular Input Line Entry System (SMILES) (Weininger 1988) and SMiles ARbitrary Target Specification (SMARTS) strings (Sayle 1997) .
Combining our previous work (Dhami et al. 2018 ) that used different similarity measures obtained from a directed graph of known chemical reactions between drugs and enzymes, transporters and inhibitors as well as the structure of the drugs in the form of SMILES and SMARTS strings and the current work which uses images of the drug structure is a natural next step. Also refining the Siamese architecture and feeding more drug images to the network are an interesting area of future work.
